|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C14orf159 |
Gene summary for C14ORF159 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C14orf159 | Gene ID | 80017 |
| Gene name | D-glutamate cyclase | |
| Gene Alias | C14orf159 | |
| Cytomap | 14q32.11 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q7Z3D6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80017 | C14orf159 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.94e-62 | 1.06e+00 | 0.294 |
| 80017 | C14orf159 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.60e-16 | 1.46e+00 | 0.3487 |
| 80017 | C14orf159 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.54e-35 | 9.01e-01 | 0.281 |
| 80017 | C14orf159 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.89e-27 | 5.75e-01 | 0.3859 |
| 80017 | C14orf159 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.94e-18 | 7.00e-01 | 0.2585 |
| 80017 | C14orf159 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.44e-19 | 3.85e-01 | 0.3005 |
| 80017 | C14orf159 | P1T-E | Human | Esophagus | ESCC | 4.92e-04 | 2.53e-01 | 0.0875 |
| 80017 | C14orf159 | P2T-E | Human | Esophagus | ESCC | 5.23e-10 | 9.07e-02 | 0.1177 |
| 80017 | C14orf159 | P4T-E | Human | Esophagus | ESCC | 7.48e-19 | 3.38e-01 | 0.1323 |
| 80017 | C14orf159 | P5T-E | Human | Esophagus | ESCC | 2.24e-10 | 1.38e-01 | 0.1327 |
| 80017 | C14orf159 | P8T-E | Human | Esophagus | ESCC | 4.47e-14 | 2.16e-01 | 0.0889 |
| 80017 | C14orf159 | P9T-E | Human | Esophagus | ESCC | 4.24e-03 | 9.83e-02 | 0.1131 |
| 80017 | C14orf159 | P10T-E | Human | Esophagus | ESCC | 6.16e-11 | 1.83e-01 | 0.116 |
| 80017 | C14orf159 | P11T-E | Human | Esophagus | ESCC | 1.67e-06 | 3.88e-01 | 0.1426 |
| 80017 | C14orf159 | P12T-E | Human | Esophagus | ESCC | 1.42e-23 | 4.72e-01 | 0.1122 |
| 80017 | C14orf159 | P15T-E | Human | Esophagus | ESCC | 5.14e-26 | 5.14e-01 | 0.1149 |
| 80017 | C14orf159 | P16T-E | Human | Esophagus | ESCC | 3.90e-09 | 1.13e-01 | 0.1153 |
| 80017 | C14orf159 | P17T-E | Human | Esophagus | ESCC | 4.10e-03 | 2.52e-01 | 0.1278 |
| 80017 | C14orf159 | P20T-E | Human | Esophagus | ESCC | 2.24e-05 | 1.61e-01 | 0.1124 |
| 80017 | C14orf159 | P21T-E | Human | Esophagus | ESCC | 6.19e-07 | 1.44e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C14orf159 | SNV | Missense_Mutation | c.572N>A | p.Gly191Asp | p.G191D | Q7Z3D6 | protein_coding | tolerated(0.75) | benign(0.006) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| C14orf159 | insertion | Frame_Shift_Ins | novel | c.1762_1763insCTCCCACTCCCACAGTCACCCTGGTCATTTCTAGAAGGCAACA | p.Gly588AlafsTer86 | p.G588Afs*86 | Q7Z3D6 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| C14orf159 | insertion | Frame_Shift_Ins | novel | c.330_331insGATTTTATTATATGGAGTCTAAGAACAGGCAAAAG | p.Ser111AspfsTer16 | p.S111Dfs*16 | Q7Z3D6 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| C14orf159 | SNV | Missense_Mutation | novel | c.1248N>C | p.Glu416Asp | p.E416D | Q7Z3D6 | protein_coding | tolerated(0.66) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C14orf159 | SNV | Missense_Mutation | c.1693N>G | p.Gln565Glu | p.Q565E | Q7Z3D6 | protein_coding | tolerated(0.68) | benign(0.003) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| C14orf159 | SNV | Missense_Mutation | rs748707396 | c.809N>A | p.Cys270Tyr | p.C270Y | Q7Z3D6 | protein_coding | tolerated(0.84) | benign(0) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| C14orf159 | SNV | Missense_Mutation | c.1546N>A | p.Asp516Asn | p.D516N | Q7Z3D6 | protein_coding | deleterious(0.04) | benign(0.341) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C14orf159 | SNV | Missense_Mutation | c.869N>A | p.Ser290Asn | p.S290N | Q7Z3D6 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| C14orf159 | SNV | Missense_Mutation | rs776230660 | c.940N>T | p.Arg314Trp | p.R314W | Q7Z3D6 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| C14orf159 | SNV | Missense_Mutation | c.70N>T | p.Pro24Ser | p.P24S | Q7Z3D6 | protein_coding | tolerated(0.41) | benign(0.009) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |